Production of active Exendin-4 in Nicotiana benthamiana and its application in treatment of type-2 diabetics

被引:4
|
作者
Akter, Shammi [1 ]
Afrin, Shajia [2 ]
Kim, Jaeyoon [2 ]
Kang, Joohyun [1 ]
Razzak, Md Abdur [1 ]
Berggren, Per-Olof [3 ]
Hwang, Inhwan [1 ]
机构
[1] Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea
[2] BioN Inc, Dept Res & Dev, Pohang, South Korea
[3] Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, Stockholm, Sweden
来源
基金
新加坡国家研究基金会;
关键词
Exendin-4; type-2; diabetics; enterokinase; insulin; recombinant protein production; INSULIN-SECRETION; EXPRESSION; PROTEIN; CHLOROPLASTS; PURIFICATION; EFFICACY; SEQUENCE; RECEPTOR; LEVEL; MICE;
D O I
10.3389/fpls.2022.1062658
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
GLP-1 (Glucagon-like peptide-1) is a peptide that stimulates insulin secretion from the beta-cell for glycemic control of the plasma blood glucose level. Its mimetic exenatide (synthetic Exendin-4) with a longer half-life of approximately 3.3-4 h is widely used in clinical application to treat diabetes. Currently, exenatide is chemically synthesized. In this study, we report that the GLP-1 analogue recombinant Exendin-4 (Exdn-4) can be produced at a high level in Nicotiana benthamiana, with an estimated yield of 50.0 mu g/g fresh biomass. For high-level expression, we generated a recombinant gene, B:GB1:ddCBD1m:8xHis : Exendin-4 (BGC : Exdn-4), for the production of Exendin-4 using various domains such as the BiP signal peptide, the GB1 domain (B1 domain of streptococcal G protein), a double cellulose binding domain 1 (CBD1), and 8 His residues (8xHis) to the N-terminus of Exendin-4. GB1 was used to increase the expression, whereas double CBD1 and 8xHis were included as affinity tags for easy purification using MCC beads and Ni2+-NTA resin, respectively. BGC : Exdn-4 was purified by single-step purification to near homogeneity using both Ni2+-NTA resin and microcrystalline cellulose (MCC) beads. Moreover, Exdn-4 without any extra residues was produced from BGC : Exdn-4 bound onto MCC beads by treating with enterokinase. Plant-produced Exdn-4 (Exendin-4) was as effective as chemically synthesized Exendin-4 in glucose-induced insulin secretion (GIIS) from mouse MIN6m9 cells a pancreatic beta cell line.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
    Fineman, MS
    Bicsak, TA
    Shen, LZ
    Taylor, K
    Gaines, E
    Varns, A
    Kim, D
    Baron, AD
    DIABETES CARE, 2003, 26 (08) : 2370 - 2377
  • [22] Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state
    Arrnes, Luis
    Moreno, Paola
    Nuche-Berenguer, Bernardo
    Valverde, Isabel
    Villanueva-Penacarrillo, Maria L.
    REGULATORY PEPTIDES, 2009, 153 (1-3) : 88 - 92
  • [23] Increased collagen production of human hepatic stellate cells (Ito Cells) induced by Exendin-4 (Exenatide) treatment
    Firneisz, G.
    Baghy, K.
    Kiss, K.
    Varga, T.
    Nagy, G.
    Kovalszky, I.
    Somogyi, A.
    DIABETOLOGIA, 2010, 53
  • [24] The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes
    Egan, JM
    Clocquet, AR
    Elahi, D
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03): : 1282 - 1290
  • [25] Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Nielsen, LL
    Young, AA
    Parkes, DG
    REGULATORY PEPTIDES, 2004, 117 (02) : 77 - 88
  • [26] GLP-1 and exendin-4 increase post-prandial leptin in type 2 diabetes
    Stoeckli, R
    Maksoud, H
    Manley, SE
    Levy, JC
    DIABETOLOGIA, 2005, 48 : A201 - A201
  • [27] Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model
    Suzuki, Kenichi
    Kim, Kyoung Sub
    Bae, You Han
    JOURNAL OF CONTROLLED RELEASE, 2019, 294 : 259 - 267
  • [28] Exendin-4 Increased Bone Mineral Density through Osteocyte in Normal and Type 2 Diabetic Rat
    Kim, Ju-Young
    Lee, Seong-Kyu
    Jo, Kyung-Jin
    Kim, Ji-Hyun
    Lim, Dong-Mee
    Lee, Kang -Woo
    Park, Keun-Young
    Koh, Gwanpyo
    Kim, Byung-Joon
    DIABETES, 2011, 60 : A483 - A483
  • [29] A COMPARISON OF THE METABOLIC PROFILES IN TYPE-2 DIABETICS DURING GLIPIZIDE AND GLIBENCLAMIDE TREATMENT
    TAYLOR, R
    ISLES, TE
    MCLAREN, S
    NEWTON, RW
    DIABETOLOGIA, 1981, 21 (03) : 335 - 335
  • [30] Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy
    Chen, Wei
    Wang, Guohao
    Yung, Bryant C.
    Liu, Gang
    Qian, Zhiyong
    Chen, Xiaoyuan
    ACS NANO, 2017, 11 (05) : 5062 - 5069